DNA and Viral Vector Vaccine Experts are leading the charge in the development of innovative vaccine technologies that harness genetic material to trigger immune responses. DNA vaccines use plasmids—small, circular pieces of DNA—to deliver instructions to cells to produce specific proteins that stimulate immunity. Meanwhile, viral vector vaccines employ modified viruses to carry genetic material into cells, prompting them to create antigens that activate the immune system. These scientists focus on refining and optimizing these platforms, ensuring their safety, efficacy, and scalability for widespread use. Their work is crucial in addressing complex diseases and has been instrumental in accelerating vaccine development timelines, offering a promising alternative to traditional vaccine methods.
These experts also work on enhancing the delivery systems of DNA and viral vector vaccines to improve stability, reduce production costs, and increase global accessibility. Through rigorous preclinical and clinical trials, they test the safety and effectiveness of these vaccines, refining their formulations based on data. DNA and viral vector vaccines have shown promise in combating diseases such as COVID-19, Ebola, and Zika , and their potential to target a wide array of conditions, including cancer, continues to expand. DNA and viral vector vaccine experts are reshaping the future of immunization, providing faster, adaptable solutions for global health challenges. Their groundbreaking work is crucial in advancing vaccine science and offering hope for a future where more diseases can be prevented with innovative vaccines.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States